Skip to main content
Patient-Centered Outcomes Research Institute
Patient-Centered Outcomes Research Institute
  • Blog
  • Newsroom
  • Find It Fast
  • Help Center
  • Subscribe
  • Careers
  • Contact Us

PCORI

Patient-Centered Outcomes Research Institute

Search form

  • About Us
    Close mega-menu

    About Us

    • Our Programs
    • Governance
    • Financials and Reports
    • Procurement Opportunities
    • Our Staff
    • Our Vision & Mission
    • Contact Us

    Fact Sheets: Learn More About PCORI

    Download fact sheets about out work, the research we fund, and our programs and initiatives.

    Find It Fast

    Browse through an alphabetical list of frequently accessed and searched terms for information and resources.

    Subscribe to PCORI Email Alerts

    Sign up for weekly emails to stay current on the latest results of our funded projects, and more.

  • Research & Results
    Close mega-menu

    Research & Results

    • Explore Our Portfolio
    • Evaluating Our Work
    • Research Results Highlights
    • Putting Evidence to Work
    • Peer Review
    • Evidence Synthesis
    • About Our Research

    Evidence Updates from PCORI-Funded Studies

    These updates capture highlights of findings from systematic reviews and our funded research studies.

    Journal Articles About Our Funded Research

    Browse through a collection of journal publications that provides insights into PCORI-funded work.

    Explore Our Portfolio of Funded Projects

    Find out about projects based on the health conditions they focus on, the state they are in, and if they have results.

  • Topics
    Close mega-menu

    Topics

    • Addressing Disparities
    • Arthritis
    • Asthma
    • Cancer
    • Cardiovascular Disease
    • Children's Health
    • Community Health Workers
    • COVID-19
    • Dementia and Cognitive Impairment
    • Diabetes
    • Intellectual and/or Developmental Disabilities
    • Kidney Disease
    • Maternal Morbidity and Mortality
    • Medicaid
    • Men's Health
    • Mental and Behavioral Health
    • Minority Mental Health
    • Multiple Chronic Conditions
    • Multiple Sclerosis
    • Obesity
    • Older Adults' Health
    • Pain Care and Opioids
    • Rare Diseases
    • Rural Health
    • Shared Decision Making
    • Telehealth
    • Transitional Care
    • Veterans Health
    • Women's Health

    Featured Topic: Women's Health

    Learn more about the projects we support on conditions that specifically or more often affect women.

  • Engagement
    Close mega-menu

    Engagement

    • The Value of Engagement
    • Engagement in Health Research Literature Explorer
    • Influencing the Culture of Research
    • Engagement Awards
    • Engagement Resources
    • Engage with Us

    Engagement Tools and Resources for Research

    This searchable peer-to-peer repository includes resources that can inform future work in patient-centered outcomes research.

    Engagement Awards

    Learn about our Engagement Awards program and view the announcements of all our open funding opportunities.

    Research Fundamentals: A New On-Demand Training

    It enables those new to health research or patient-centered research to learn more about the research process.

  • Funding Opportunities
    Close mega-menu

    Funding Opportunities

    • What & Who We Fund
    • What You Need to Know to Apply
    • Applicant Training
    • Merit Review
    • Awardee Resources
    • Help Center

    PCORI Funding Opportunities

    View and learn about the newly opened funding announcements and the upcoming PFAs in 2021.

    Tips for Submitting a Responsive LOI

    Find out what PCORI looks for in a letter of intent (LOI) along with other helpful tips.

    PCORI Awardee Resources

    These resources can help awardees in complying with the terms and conditions of their contract.

  • Meetings & Events
    Close mega-menu

    Meetings & Events

    • Upcoming
    • Past Events

    PCORI 2021 and Beyond

    During this webinar, PCORI leaders shared ways to get involved in PCOR, improvements to our funding opportunities, and more.

    2020 PCORI Annual Meeting

    Watch recordings of sessions and view titles and descriptions of posters presented at the virtual meeting.

    Board Approves Future PFA Topics at April Meeting

    The more than a dozen high-priority research topics will be considered for PCORI Funding Announcements (PFAs) that will be released this fall and in 2022.

You are here

  • Research & Results
  • Explore Our Portfolio
  • The Comparative Effectiveness and Saf...

The Comparative Effectiveness and Safety of Four Second-Line Pharmacological Strategies in a Type 2 Diabetes Study (The CER-4-T2D Study)

Sign Up for Updates to This Study  

Project Summary  

Over 34 million Americans have diabetes, and cardiovascular disease is the leading cause of illness and death in this population. In recent randomized controlled trials (RCTs) mostly including patients with diabetes at high cardiovascular risk, two classes of medications to treat hyperglycemia, SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA), reduced the risk of cardiovascular events, mortality, and kidney disease. Current clinical guidelines do not offer clear guidance regarding the optimal second-line glucose-lowering treatment in patients with type 2 diabetes. This barrier results from (1) unavailability of RCTs comparing diabetes medications head-to-head for hard clinical endpoints or drug-related harms, and (2) underrepresentation of patients at low to moderate cardiovascular risk in RCTs. This gap leaves the majority of patients with type 2 diabetes, their clinicians, and other stakeholders seeking more information to help select the best second-line medication to treat hyperglycemia.

This study will answer the question that most patients and their healthcare providers face when metformin is insufficient to manage hyperglycemia: Which glucose-lowering medications should patients with type 2 diabetes with moderate cardiovascular disease and their providers add, to best balance tradeoffs in benefits and risks? The results of this study will have an immediate and widespread impact on medical practice by informing decision making related to the comparative effectiveness and safety of the four most frequently used second-line agents for patients with type 2 diabetes, their clinicians, and other key stakeholders.

The comparative effectiveness and safety of four second-line pharmacological strategies in the type 2 diabetes study (The CER-4-T2D Study) aims to compare SGLT2i, GLP-1RA, dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU) head-to-head, focusing on the following:

  • Their effectiveness, including their effect on cardiovascular events, mortality, renal events, and other patient-centered outcomes, in the overall population of patients with type 2 diabetes and moderate cardiovascular risk, and in subgroups of interest, such as patients with chronic kidney disease and older frail individuals
  • Their safety, including their association with previously reported drug-related harms (e.g., diabetic ketoacidosis, fractures, amputations, pancreatitis, severe hypoglycemia) and unanticipated drug-related adverse events. The study will also develop tools to identify patients with a higher likelihood of drug-related harms.

The CER-4-T2D study will use real-world data from health insurance claims and electronic health records to study patients with type 2 diabetes routinely treated with glucose-lowering medications. Specifically, the study will identify real-world patients who start treatment with SGLT2i, GLP-1RA, DPP-4i, or SU, and will follow them for outcomes that might occur after treatment initiation. SGLT2i, GLP-1RA, DPP-4i, or SU will be compared among each other at the class and at the individual medication levels.

Primary outcomes will include major cardiovascular events (e.g., myocardial infarction, stroke, heart failure) and mortality. Secondary outcomes of interest will include kidney disease, blood sugar control, weight, persistence on prescribed medication and patterns of medication switching, home time (i.e., time spent outside of hospital or nursing facilities), and potential drug-related harms (e.g., diabetic ketoacidosis, bone fractures, lower limb amputations, urogenital infections, low blood sugar episodes, acute kidney injury, pancreatitis, gallbladder or biliary events, retinopathy).

We convened and engaged a Stakeholder Advisory Panel to ensure that we are able to prioritize study aspects that are of substantial interest to stakeholders. The panel assisted us in formulating the study proposal and will partner with us to conduct the work to advise on study questions, outcomes, and specific analyses. The panel is currently composed of four patients with diabetes and four professional stakeholders. Our patient advisers are individuals who have used many of the medications being studied and are at moderate cardiovascular risk. They include three women and one man, ranging in age from 54 to 73. Three are white and one is black. Three are married and one is single. The professional stakeholders represent a variety of end-users of the proposed work, whose decisions will be informed by study findings. They include a community-based endocrinologist, a primary care physician with expertise in decision sciences, a pharmacist and pharmacoepidemiologist who directs the Pharmacy Quality & Utilization Program at a local hospital, and a primary care physician with expertise in academic detailing and health services research.

Project Details

Principal Investigator
Elisabetta Patorno, MD, DrPH
Project Status
Awarded; Contract pending
Board Approval Date
March 2021
Project Period *  
36 months
Organization
Brigham and Women's Hospital
Year Awarded
2021
State
Massachusetts
Project Type
Research Project
Funding Announcement
Observational Analyses of Second-Line Pharmacological Agents in Type 2 Diabetes
Project Budget *  
$4,443,087

*All proposed projects, including requested budgets and project periods, are approved subject to a programmatic and budget review by PCORI staff and the negotiation of a formal award contract.

Page Last Updated: 
March 26, 2021

Research & Results

  • Explore Our Portfolio
  • Evaluating Our Work
  • Research Results Highlights
  • Putting Evidence to Work
  • Peer Review
  • Evidence Synthesis
  • About Our Research

About Us

  • Our Programs
  • Governance
  • Financials and Reports
  • Procurement Opportunities
  • Our Staff
  • Our Vision & Mission
  • Contact Us

Research & Results

  • Explore Our Portfolio
  • Evaluating Our Work
  • Research Results Highlights
  • Putting Evidence to Work
  • Peer Review
  • Evidence Synthesis
  • About Our Research

Engagement

  • The Value of Engagement
  • Engagement in Health Research Literature Explorer
  • Influencing the Culture of Research
  • Engagement Awards
  • Engagement Resources
  • Engage with Us

Funding Opportunities

  • What & Who We Fund
  • What You Need to Know to Apply
  • Applicant Training
  • Merit Review
  • Awardee Resources
  • Help Center

Meetings & Events

April 27
Priorities on the Health Horizon: Informing PCORI's Strategic Plan (Webinar #2)
May 6
Advisory Panel on Healthcare Delivery and Disparities Research Spring 2021 Meeting
May 10
Cycle 2 2021 Nonsurgical Options for Women with Urinary Incontinence -- Applicant Town Hall

PCORI

Footer contact address

Patient-Centered Outcomes
Research Institute

1828 L Street, NW, Suite 900
Washington, DC 20036
Phone: (202) 827-7700 | Fax: (202) 355-9558
info@pcori.org

Subscribe to Newsletter

Twitter Facebook LinkedIn Vimeo

© 2011-2021 Patient-Centered Outcomes Research Institute. All Rights Reserved.

Privacy Policy | Terms of Use | Trademark Usage Guidelines | Credits | Help Center